- Home
- HSII vs TSHA Comparison
HSII vs TSHA Comparison
Compare HSII & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- TSHA
- Stock Information
- Founded
- HSII 1953
- TSHA 2019
- Country
- HSII United States
- TSHA United States
- Employees
- HSII N/A
- TSHA N/A
- Industry
- HSII Diversified Commercial Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- TSHA Health Care
- Exchange
- HSII Nasdaq
- TSHA Nasdaq
- Market Cap
- HSII 904.6M
- TSHA 728.4M
- IPO Year
- HSII 1999
- TSHA 2020
- Fundamental
- Price
- HSII $42.76
- TSHA $2.46
- Analyst Decision
- HSII Buy
- TSHA Strong Buy
- Analyst Count
- HSII 2
- TSHA 7
- Target Price
- HSII $49.00
- TSHA $7.57
- AVG Volume (30 Days)
- HSII 107.7K
- TSHA 4.9M
- Earning Date
- HSII 07-28-2025
- TSHA 08-11-2025
- Dividend Yield
- HSII 1.41%
- TSHA N/A
- EPS Growth
- HSII N/A
- TSHA N/A
- EPS
- HSII 0.37
- TSHA N/A
- Revenue
- HSII $1,116,954,000.00
- TSHA $7,224,000.00
- Revenue This Year
- HSII $6.41
- TSHA N/A
- Revenue Next Year
- HSII $2.65
- TSHA N/A
- P/E Ratio
- HSII $115.91
- TSHA N/A
- Revenue Growth
- HSII 6.10
- TSHA N/A
- 52 Week Low
- HSII $30.20
- TSHA $1.05
- 52 Week High
- HSII $49.02
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- HSII 45.73
- TSHA 45.90
- Support Level
- HSII $42.86
- TSHA $2.48
- Resistance Level
- HSII $44.14
- TSHA $2.66
- Average True Range (ATR)
- HSII 0.81
- TSHA 0.21
- MACD
- HSII -0.22
- TSHA -0.06
- Stochastic Oscillator
- HSII 21.03
- TSHA 10.14
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.